Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute ...
Discusses Clinical Update on AB8939 Combined With Venetoclax for Refractory and Relapsed AML With Poor Genetics October 16, ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback